Terns Pharmaceuticals, Inc. (TERN)

NASDAQ: TERN · IEX Real-Time Price · USD
4.560
-0.110 (-2.36%)
Apr 17, 2024, 3:27 PM EDT - Market open
-2.36%
Market Cap 294.81M
Revenue (ttm) n/a
Net Income (ttm) -90.21M
Shares Out 64.65M
EPS (ttm) -1.27
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 574,333
Open 4.720
Previous Close 4.670
Day's Range 4.500 - 4.800
52-Week Range 3.260 - 14.044
Beta -0.65
Analysts Strong Buy
Price Target 14.94 (+227.63%)
Earnings Date May 13, 2024

About TERN

Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology, metabolic dysfunction-associated steatohepatitis (MASH), and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is i... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Feb 5, 2021
Employees 66
Stock Exchange NASDAQ
Ticker Symbol TERN
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 8 analysts, the average rating for TERN stock is "Strong Buy." The 12-month stock price forecast is $14.94, which is an increase of 227.63% from the latest price.

Price Target
$14.94
(227.63% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Terns Pharmaceuticals Appoints Melita Sun Jung as Chief Business Officer

FOSTER CITY, Calif., April 10, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of smal...

6 days ago - GlobeNewsWire

This small-cap stock is expected to take off — if its weight-loss pill trial succeeds

The stock of small-cap Terns Pharmaceuticals Inc. rose 6% on Thursday, amid bullish analyst comment on the company's pipeline, which includes an oral treatment for obesity that one bank believes could...

20 days ago - Market Watch

Terns Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Updates

Interim data from initial dose escalation cohorts from Phase 1 trial of TERN-701 (allosteric BCR-ABL) for treatment of CML expected in second half of 2024

4 weeks ago - GlobeNewsWire

Terns Pharmaceuticals Announces Orphan Drug Designation Granted to TERN-701 for the Treatment of Chronic Myeloid Leukemia

FOSTER CITY, Calif., March 11, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of smal...

5 weeks ago - GlobeNewsWire

Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)

FOSTER CITY, Calif., March 07, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of smal...

5 weeks ago - GlobeNewsWire

Terns Pharmaceuticals to Participate in Upcoming March Investor Conferences

FOSTER CITY, Calif., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small...

7 weeks ago - GlobeNewsWire

Terns Pharmaceuticals Reports Inducement Grants to New Chief Executive Officer Under Nasdaq Listing Rule 5635(C)(4)

FOSTER CITY, Calif., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small...

2 months ago - GlobeNewsWire

Terns Pharmaceuticals Appoints Amy Burroughs as Chief Executive Officer

Proven Industry Executive Brings More Than 25 Years of Leadership Experience Proven Industry Executive Brings More Than 25 Years of Leadership Experience

2 months ago - GlobeNewsWire

The weight loss drug market may soon get more crowded – here are the companies trying to enter the booming space

Wall Street has been focused on Novo Nordisk, Eli Lilly and other large drugmakers hoping to join the weight loss drug market, such as Pfizer, Roche and Amgen.

Other symbols: VKTXGPCR
3 months ago - CNBC

Terns Pharmaceuticals to Highlight 2024 Priorities and Clinical Milestones at the 42nd Annual J.P. Morgan Healthcare Conference

Plans to advance diverse pipeline of programs in oncology and metabolic diseases Anticipates key proof-of-concept readouts for TERN-701 (CML) and TERN-601 (obesity) in 2H24 Prioritizing capital alloca...

3 months ago - GlobeNewsWire

Terns Pharmaceuticals to Present at the JMP Securities Hematology and Oncology Summit

FOSTER CITY, Calif., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small...

4 months ago - GlobeNewsWire

Terns Pharmaceuticals Mourns the Loss of Senthil Sundaram, Former Chief Executive Officer

FOSTER CITY, Calif., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small...

5 months ago - GlobeNewsWire

Terns Pharmaceuticals Reports Third Quarter 2023 Financial Results and Corporate Updates

Announced global Phase 1 clinical trial design of TERN-701 (allosteric BCR-ABL) for CML with patient screening anticipated in December 2023 and interim top-line data expected in the second half of 202...

5 months ago - GlobeNewsWire

Terns Pharmaceuticals Presents Late-Breaking Data from Phase 2a DUET Trial of THR-β Agonist TERN-501 in NASH at AASLD The Liver Meeting® 2023

TERN-501 treatment over 12 weeks significantly improved liver fat content and fibro-inflammation in NASH patients, with low rates of gastrointestinal and no cardiovascular adverse events

5 months ago - GlobeNewsWire

Terns Pharmaceuticals to Participate in Upcoming November Investor Conferences

FOSTER CITY, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small...

5 months ago - GlobeNewsWire

Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)

FOSTER CITY, Calif., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small...

5 months ago - GlobeNewsWire

Terns Pharmaceuticals to Participate in Upcoming Investor Conferences

FOSTER CITY, Calif., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small...

6 months ago - GlobeNewsWire

Terns Pharmaceuticals Announces Global Phase 1 Clinical Trial Design of TERN-701 for the Treatment of Chronic Myeloid Leukemia

Investigational New Drug application cleared by U.S. Food and Drug Administration Design leverages insights from partner's ongoing Phase 1 trial in China that support starting dose that appears safe a...

6 months ago - GlobeNewsWire

Terns Pharmaceuticals Reports Second Quarter 2023 Financial Results and Corporate Updates

- Terns reported positive top-line data from the Phase 2a DUET trial of TERN-501 (THR-β) in NASH, with TERN-501 meeting all primary and secondary endpoints

9 months ago - GlobeNewsWire

Terns Pharmaceuticals Announces Leadership Transition

Senthil Sundaram Stepping Down as Chief Executive Officer for Health Reasons Senthil Sundaram Stepping Down as Chief Executive Officer for Health Reasons

9 months ago - GlobeNewsWire

Terns Pharmaceuticals to Host Virtual Key Opinion Leader Event to Discuss TERN-701 and Advances in the Treatment Landscape for Chronic Myeloid Leukemia

FOSTER CITY, Calif., July 18, 2023 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small...

9 months ago - GlobeNewsWire

Terns Pharmaceuticals Highlights New Preclinical Data for TERN-601 Program in Obesity at the ADA's 83rd Annual Scientific Session and Upcoming Events

TERN-601 significantly improved glucose tolerance, suppressed food intake and slowed gastric emptying in a preclinical transgenic mouse model

10 months ago - GlobeNewsWire

Terns Pharmaceuticals to Present at Goldman Sachs 44th Annual Global Healthcare Conference

FOSTER CITY, Calif., June 06, 2023 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small...

11 months ago - GlobeNewsWire

Terns Pharmaceuticals Announces Publication of TERN-701 Trial-in-Progress Abstract for the 2023 ASCO Annual Meeting

- Enrollment progress update from ongoing China Phase 1 trial of TERN-701 (allosteric BCR-ABL) to be presented at ASCO 2023

11 months ago - GlobeNewsWire

Terns Pharmaceuticals to Present at Upcoming Investor Conferences

FOSTER CITY, Calif., May 24, 2023 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-...

11 months ago - GlobeNewsWire